The rabbit monoclonal antibody r40 specifically binds to HER2 ECD III/IV and, similar to trastuzumab, inhibits breast cancer cell proliferation by suppressing the PI3K/AKT and MAPK signaling pathways through reduction of HER2 protein expression. Here, AKT1 is linked to breast cancer.